

Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange

Chimno I. Nnadi,[†] Meredith L. Jenkins,[‡] Daniel R. Gentile,[†] Leslie A. Bateman,[§] Daniel Zaidman,^{||} Trent E. Balius,[⊥] Daniel K. Nomura,[§] John E. Burke,[‡] Kevan M. Shokat,[†] and Nir London^{*,||}

[†]Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California 94158, United States

[‡]Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8W 2Y2, Canada


[§]Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California 94720, United States

^{||}Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, 7610001, Israel

[⊥]Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States

Supporting Information

ABSTRACT: The success of targeted covalent inhibitors in the global pharmaceutical industry has led to a resurgence of covalent drug discovery. However, covalent inhibitor design for flexible binding sites remains a difficult task due to a lack of methodological development. Here, we compared covalent docking to empirical electrophile screening against the highly dynamic target K-Ras^{G12C}. While the overall hit rate of both methods was comparable, we were able to rapidly progress a docking hit to a potent irreversible covalent binder that modifies the inactive, GDP-bound state of K-Ras^{G12C}. Hydrogen–deuterium exchange mass spectrometry was used to probe the protein dynamics of compound binding to the switch-II pocket and subsequent destabilization of the nucleotide-binding region. SOS-mediated nucleotide exchange assays showed that, contrary to prior switch-II pocket inhibitors, these new compounds appear to accelerate nucleotide exchange. This study highlights the efficiency of covalent docking as a tool for the discovery of chemically novel hits against challenging targets.



INTRODUCTION

Covalent inhibitors were specifically avoided by the pharmaceutical industry until recently, due to concerns of off-target toxicity.^{1,2} The recent approval of afatinib, ibrutinib, and osimertinib, which target nonconserved cysteines in the adenosine triphosphate (ATP) binding site of kinases, has accelerated interest in covalent drug discovery. These irreversible kinase inhibitors were developed using potent reversible ATP binding-site ligands as a starting scaffold, which are then endowed with an acrylamide-based electrophile (“warhead”). This approach allows the use of a mild electrophile, while relying on the potent reversible binding affinity of the inhibitor to “present” the warhead to the targeted cysteine.³

A much more challenging target is exemplified by K-Ras which has no high affinity reversible ligands except the endogenous GDP/GTP nucleotides ($K_D \sim \text{pM}$).⁴ K-Ras is a small G protein that acts as molecular switch to activate mitogenic signaling pathways in the presence of growth factors. Mutations to the K-Ras pathway, including G12C, render K-Ras constitutively active leading to aberrant cell proliferation. K-Ras^{G12C} is implicated in 40% of K-Ras-driven lung

adenocarcinomas. A fragment-based tethering screen was used in order to discover the first K-Ras^{G12C} allosteric inhibitor.⁵ Tethering is carried out with reversible covalent disulfides to identify thermodynamically favorable interactions with the protein target. Covalent bond formation in this screen can be attenuated with a stringency factor (usually by adjusting the levels of 2-mercaptoethanol).⁶ Following hit discovery, further medicinal chemistry is required to convert disulfide hits from the screen to carbon-based electrophiles that are compatible with the cellular environment. This conversion can be challenging.

The optimization of the K-Ras^{G12C} irreversible ligands has yielded two important insights: (1) The determination of multiple co-crystal structures revealed a highly flexible ligand binding pocket (termed switch-II pocket; S-IIP) beneath the switch-II loop. (2) Even the best irreversible inhibitors show only weak ($>200 \mu\text{M}$) binding in the absence of the warhead.^{5,7} These findings were initially thought to limit the druggability of K-Ras^{G12C}. Recently, however, potent on-target inhibition of K-

Received: June 29, 2017

Published: January 10, 2018




Figure 1. (a) Summary of screening methods for covalent ligand discovery. (b) Pairwise Tanimoto scores for each library were generated using ECFP4 fingerprints and presented as a 50-bin histogram.

Ras^{G12C} has been validated extensively.^{7–9} These molecules allosterically trap K-Ras^{G12C} in the inactive GDP-bound state by preventing SOS-mediated nucleotide exchange. Covalent inhibition by modification of G12C allows oncogene specific inhibition by sparing the wild-type protein from inhibition, which is predicted to contribute to the ultimate therapeutic index in patients.

Recognizing the growing importance of covalent drug discovery and the unique features of flexible protein targets like K-Ras^{G12C}, we set out to compare one empirical screening approach and a virtual screening approach to discover new K-Ras^{G12C} binders. There is little information on how covalent electrophile libraries fare in comparison to other screening approaches.¹⁰ We tested a fragment-based acrylamide library using mass spectrometry in conjunction with covalent virtual screening via DOCKoValent, a structure-based virtual screening algorithm that predicts covalent ligand binding to a target receptor.¹¹ Unlike disulfide tethering, the latter two approaches directly screen compounds containing the reactive warheads (e.g., acrylamides) for optimal ligand–receptor geometry, thereby simplifying downstream medicinal chemistry.

Simulating protein flexibility is a major challenge for molecular docking.¹² K-Ras is a highly dynamic target. Many of the 24 inhibitor-bound K-Ras^{G12C} crystal structures that were available at the start of this study showed altered pocket topology due to switch-II loop flexibility and induced fit around structurally diverse ligands. Accounting for flexibility is a challenge in docking and many methods have been explored in the literature.^{12–20} However, these methods can often reduce predictive success by increasing false positives, demonstrated in retrospective calculations that confirm the loss of enrichment of known ligands over decoys.^{21–26} Here, we utilized the enrichment of a known ligand as the selection criteria for picking the best receptor structure for molecular docking.

Previously, DOCKoValent was used to discover *reversible* covalent inhibitors. This is the first prospective study using DOCKoValent to find *irreversible* inhibitors of a target, specifically K-Ras^{G12C}. We show that covalent docking is comparable to screening a small library of electrophilic fragments in terms of hit rate and off-target reactivity. We find that covalent docking in combination with orthogonal

biophysical methods such as the thermal stability assay and hydrogen–deuterium exchange mass spectrometry can successfully identify novel irreversible compounds with favorable potency and specificity for K-Ras^{G12C}. Furthermore, covalent docking produced compounds that are structurally diverse and which exert dramatically different biochemical effects from compounds discovered using disulfide tethering approaches previously applied to the same target.

RESULTS AND DISCUSSION

Docking Guided Template Selection. Structures of 24 distinct monomers of K-Ras^{G12C} in complex with a covalent compound were available for docking (Table S1). Superimposing all of the different structures illustrates the significant flexibility of the switch-II region and the caveats of docking to a static structure (Figure S1).

In order to select a suitable structure for the docking screen, we first attempted to computationally recapitulate the previous empirical tethering screen results from Ostrem et al.⁵ The original tethering library of 480 compounds has since doubled in size. We covalently docked this library of 960 disulfide-containing compounds as a more stringent test for enriching known binders. We identified the best candidate for docking (PDB: 4M1S chain B) as the structure that enriches for compound 6H05, the best reported K-Ras^{G12C} tethering hit (94 ± 1% modification of K-Ras^{G12C}, Figure S2a).⁵ Compound 6H05 ranked 15/960 for this structure (top 2%). The docking pose placed the *p*-chloro-benzene in the hydrophobic region of S-IIP (Figure S2b) as observed in the co-crystal structure of a 6H05 analogue in complex with K-Ras^{G12C} (PDB: 4LUC).

We then used 4M1S chain B to dock a test set of 110 previously synthesized vinylsulfonamide-based compounds in structure–activity relationship (SAR) efforts to find more potent S-IIP binders. Vinylsulfonamide 13, the crystallographic ligand in 4M1S, ranked fourth out of this library, closely recapitulating the crystallographic binding mode (1.35 Å rmsd; Figure S2c–d). These results, in which both disulfide hits and carbon-based electrophiles were correctly selected by the program, encouraged us to use 4M1S chain B for a large-scale virtual screen against K-Ras^{G12C}.

Covalent Library Design and Docking. Prior efforts to generate K-Ras^{G12C} compounds have relied on disulfide tethering as a starting point to generate the high affinity reversible binding element.^{5,6} However, conversion of a disulfide to a carbon-based electrophile requires iterative optimization of electrophile geometry and linker length to successfully engage the target cysteine. DOCKovalent directly screens carbon electrophiles and, in doing so, optimizes ligand orientation and electrophile position.

In addition to electrophile orientation, the tuning of electrophile reactivity also represents a challenge to the design of covalent inhibitors.²⁷ Overly reactive electrophiles may have promiscuous off-target effects, while nonreactive electrophiles may not be able to form a covalent bond with the target. Unsubstituted acrylamides are found in clinically approved agents and are considered mild electrophiles that react with nucleophilic cysteines when receptor and ligand geometry is optimized.²⁸

To computationally explore a diverse set of acrylamides, we constructed two virtual libraries based on fragment-like (xLogP ≤ 3.5 , molecular weight ≤ 250 , number of rotatable bonds ≤ 5) primary ($N = 28\,350$) and secondary ($N = 31\,949$) aliphatic amines (Figure 1a).²⁹ Pairwise Tanimoto scores for all the compounds in the DOCKovalent virtual library, the acrylamide physical library and the disulfide tethering library showed increased ligand diversity in the covalent docking library (Figure 1b). Acrylamides were generated *in silico* from the amine building blocks. The ligands' conformations, stereoisomers, and protonation states were then precomputed to allow for rapid docking.

In K-Ras^{G12C} crystal structures, cysteine 12 usually samples two favored rotamers: (1) facing the nucleotide binding site, often seen in apo structures and (2) toward the switch-II pocket observed in ligand-bound G12C structures. These rotamers have been observed in structures with different space groups and unit cell dimensions, suggesting that they are not predetermined by crystallographic conditions. Using DOCKovalent 3.6,¹¹ we docked the two libraries to both putative rotamers of cysteine 12 ($\chi_1 = -169.9^\circ, -69.8^\circ$) in 4M1S chain B. The top 500 compounds (top 1.5% of each library) from each screen were manually inspected and filtered for criteria that are not assessed by the docking energy function such as internal ligand strain, unlikely protonation states, correct representation of the ligand in the docking pose, synthetic accessibility and commercial availability of the amine-based building blocks.

Docking and Empirical Screening Show Similar Hit Rates. Twenty-nine compounds from the covalent docking library were selected, synthesized, and experimentally tested against cys-light K-Ras^{G12C} (a truncated construct, residues 1–169, that contains only a single cysteine at position 12). For the empirical screening set, we screened an acrylamide subset ($N = 62$) of a carbon electrophile library (Table S2–3). To assess off-target reactivity, we also tested compound engagement to full length K-Ras^{WT} 1–189, which contains additional cysteines including a highly reactive, flexible C-terminal C185. Overall, the two libraries showed comparable hit rates (7–15%) and reactivity profile (Table 1). The electrophile library contained more promiscuous acrylamides overall than the docking library (Table 1). We highlight examples of acrylamides from each library, hits 1–4, which are moderately reactive to both G12C and the control, K-Ras^{WT} 1–189 (Figure 2a and b).

Table 1. Results of Mass-Spectrometry Based Screen of Electrophile Library and DOCKovalent Library

	electrophile library	DOCKovalent library
library size	94	60299
MW	150–300	<300
assayed	62	29
hits	9	2
nonspecific hits	7	1
WT binders	21	7

We chose to pursue acrylamide 1 from the covalent docking library based on its high reactivity to K-Ras^{G12C} (Figure 2a and b), its novelty compared to known K-Ras^{G12C} binders,⁵ and the chemical tractability of its scaffold. The proline linker offers only a few rotatable bonds, which may sample a few conformationally constrained orientations to produce the final binding pose in which the linker rigidly inserts the naphthalene into the hydrophobic S-IIP (Figure 2c). Analysis of the docking poses of the binders revealed that only compound 1 showed the potential for hydrogen bond formation, specifically to R68. We also investigated the potential binding pose of compound 1 using DOCK3.6 (reversible docking), which does not constrain the covalent bond. The pose produced by DOCK3.6 recapitulates the DOCKovalent pose with only a slight rotation of the amide bond of the pyrrolidine-2-carboxamide linker (Figure S3a).

Docking Hit Could Be Optimized to a Selective, Potent Binder. We used the docking model in combination with commercially available building blocks to expedite compound optimization (Table 2). By contrast, previous efforts starting with a disulfide tethering hit required extensive medicinal chemistry to convert the disulfide fragments to acrylamides. In addition to labeling the G12C residue, acrylamide 1 exhibited nonspecific labeling of K-Ras^{WT}, which was a feature important to address during the chemical optimization of the scaffold. The docking model (Figure S4) suggested that hydrophobic substitutions around the naphthalene moiety might be tolerated. Indeed, the testing of a series of substitutions led to the discovery of the 6-bromo-naphthalene modification with improved labeling of 85% (200 μM ; 24 h; 25 $^\circ\text{C}$). Structure–activity relationship analysis of acrylamide 1 also suggested that alterations to the proline linker fine-tuned acrylamide specificity and compound affinity (Table 2). For example, substitution of D-proline for the L-proline abrogated G12C-specific reactivity but maintained comparable labeling to the wild type K-Ras. Additional modification of the proline linker to *cis*-3-hydroxy-L-proline led to the most potent acrylamide 10 (Figure 3a). The proline modification substantially improved the potency of 10, which was able to reach 78% labeling at 25 μM . Compound 10 also does not rely on the binding affinity of a chemically reactive phenol from the early generation G12C inhibitors, which represents an improvement in the druglikeness of the chemical scaffold.^{5,7}

This compound only labels G12C in the GDP-bound state and does not label endogenous cysteines in the wild-type K-Ras 4B construct (Figure 3b). Compound 10 does not react with the active state of Ras, as indicated by the lack of binding to K-Ras^{G12C} GppNHp. This is comparable to results using a previously reported switch-II inhibitor, compound 11, which was discovered through tethering (Figure 3a).

New Compound Accelerates Nucleotide Exchange. We examined the effect of these compounds on the nucleotide




Figure 2. (a) Percent modification of K-Ras^{WT} 1–189 vs cys-light K-Ras^{G12C} 1–169 by compounds in the docking library (blue) or the empirical library (red). (b) Potential hits from each library. (c) DOCKovalent pose of compound 1 bound to K-Ras^{G12C}. (d) DOCKovalent pose of compound 2 bound to K-Ras^{G12C}.

Table 2. Compound 1 Analogue Structure–Activity Relationship^a

Compound		K-Ras ^{G12C} 1–169	K-Ras ^{WT} 1–189
1		34% [+/-2]	41% [+/-1]
5		0% [+/-0]	51% [+/-2]
6		65% [+/-3]	66% [+/-1]
7		85% [+/-1]	38% [+/-3]
8		43% [+/-7]	29% [+/-2]
9		100% [+/-0]	57% [+/-1]

^aPercentages represent adduct formation to cys-light K-Ras^{G12C} 1–169 or K-Ras^{WT} 1–189 with 200 μ M compound after 24 h at 25 $^{\circ}$ C by mass spectrometry (\pm SD, $n = 3$).

exchange rate of K-Ras *in vitro* using a fluorescence nucleotide exchange assay. SOS-catalyzed exchange of BODIPY-FL GDP and BODIPY-FL GTP in K-Ras^{G12C} GDP constructs showed increased exchange of both fluorescent nucleotides in the presence of compound 10 but not with 11 (Figure 3c and d). Acrylamide inhibitors of K-Ras^{G12C} have previously favored GDP binding due to strong steric clash with the γ -phosphate of GTP as well as disruption of key side chain interactions with the terminal phosphate.^{5,7} The mass spectrometry experiments show that 10 prefers to bind inactive K-Ras^{G12C} as well. After reacting with G12C, compound 10 may destabilize the switch I

region or phosphate loop and cause increased nucleotide cycling.

Structural Determination of K-Ras^{G12C} in Complex with 10. We attempted to crystallize cys-light K-Ras^{G12C} bound to compound 10 using various methods including co-crystallization, soaking, and seeding using preformed crystals from a different S-IIP inhibitor. Co-crystallization experiments were successful, and we determined a co-crystal structure of K-Ras^{G12C} covalently bound to compound 10 to 1.75 \AA resolution (PDB:6ARK). Crystallographic evidence reaffirms that the molecule is bound to G12C and suggests that the ligand interaction to the protein is weak (Figure 3e–g). Well-defined electron density confirmed compound 10 was covalently bound to G12C. However, 10 did not occupy the switch-II pocket in the crystal structure but, rather, was making nearby van der Waals interactions with the $\alpha 2$ (switch-II) helix of a nearby symmetry mate (Figure 3f and g; $F_o - F_c$ at 2.0 σ). This characteristic is not unique to compound 10, as other early stage switch-II binders were crystallized with binding poses outside the ligand-binding site. It is unlikely that the crystallographic pose represents the in-solution binding pose. The crystallographic pose may, however, indicate that 10 is not stable in the S-IIP site following the formation of the covalent bond to G12C.

Compound Binding Destabilizes K-Ras. In order to assay the protein dynamics of K-Ras bound to 10 and 11, we utilized hydrogen–deuterium exchange mass spectrometry (HDX-MS; Figure 4). HDX-MS is a technique that measures the exchange rate of amide hydrogens with deuterated solvent, and since the main determinant of amide exchange is their involvement in secondary structure, it is an excellent probe of protein dynamics.^{30,31} Experiments were carried out for five time points of H/D exchange (0.3, 3, 30, 300, and 3000 s) in deuterated buffer at pH 7.5. HDX-MS data of K-Ras^{G12C} bound to GDP were consistent with previously published reports, confirming the flexibility of both the switch-I and switch-II loops.³²




Figure 3. (a) Structures of compound 10 and switch-II inhibitor 11. (b) Percentages represent adduct formation to K-Ras constructs with 25 μ M compound over 24 h at 25 $^{\circ}$ C. Sos-catalyzed exchange of apo and compound-labeled K-Ras^{G12C} GDP with (c) BODIPY-FL GDP and (d) BODIPY-FL GTP and fluorescence intensity was monitored over time. (e) Co-crystal structure of 10 (blue) and K-Ras^{G12C} GDP (gray; PDB: 6ARK). (f) $F_o - F_c$ omit map (gray mesh, 2.0 σ) of 10 covalently bound to Cys12. (g) Cartoon representation of p-loop (slate), Cys12, and 10 (blue) with indicated residues that make hydrophobic contacts with 10 in a nearby symmetry mate (white).




Figure 4. (a) Relative hydrogen–deuterium exchange differences between compound 11-bound K-Ras^{G12C} GDP and apo K-Ras^{G12C} GDP represented on co-crystal structure with compound 11 (PDB: 4M21). Dashed lines represent disordered regions. (b) Hydrogen–deuterium exchange differences between compound 10-bound K-Ras^{G12C} GDP and apo K-Ras^{G12C} GDP represented on the docking pose. (c) Thermal stability assay on K-Ras^{G12C} with compounds 10 and 11. (d) T_{50} melting temperatures.

Numerous changes in H/D exchange were observed when comparing apo K-Ras^{G12C} GDP to K-Ras^{G12C} modified by compound 10 or 11. Compound 11 is a confirmed switch-II-binder (PDB: 4M21) and showed decreased exchange in the interswitch region (IR) composed of $\beta 2$ and $\beta 3$ as well as the switch-II region (Figure 4). Comparatively, 10 also showed

decreases in exchange in the IR and switch-II regions and increased exchange of the $\alpha 3$ and $\alpha 4$ helices.

To assess whether compound binding to K-Ras was in a favorable conformation after covalent bond formation, we used a thermal stability assay which measures the thermal shift associated with compound binding. Recent studies have

demonstrated that compound stabilization correlates with increased potency.³³ For example, compound 12 in the work of Ostrem et al. showed marked improvement in labeling of G12C (100% labeling using 10 μ M compound)⁵ and also thermal stabilization of K-Ras^{G12C} by 4 °C (Figure S5). Compounds 10 and 11 induce 4.7 and 2.4 °C destabilization of K-Ras respectively (Figure 4c and d), indicating they may be destabilizing core regions of the protein upon binding. For compound 10 this is consistent with the increases in H/D exchange observed throughout large regions of the protein. Further structure-activity-relationships will be critical to increase the potency of compound 10.

CONCLUSIONS

This is the first prospective application of DOCKoValent toward finding an *irreversible* covalent inhibitor. From the results of this study, covalent docking appears to significantly accelerate early hit discovery against a very challenging and flexible target. The initial screen revealed that 2 of 29 compounds could react with K-Ras^{G12C}, a 7% success rate. These results were comparable to an empirical electrophile library screen. DOCKoValent does not take into account the variability of the acrylamide warhead electronics at the covalent attachment point.¹⁰ It is therefore encouraging that it was able to rank two fragments that successfully engage the protein without being overly promiscuous. Future incorporation of warhead reactivity or covalent reversible warheads may further reduce false positive hits from docking.^{11,27} Although the hit rates were not as high as previous covalent docking campaigns,¹¹ the success rate was still comparable to typical noncovalent virtual screening hit rates.

From the docking hit, we generated a chemically distinct G12C binder which lacked the chemically reactive phenol from the original scaffold.^{5,7} Early generation switch-II pocket inhibitors gained potency through modifications that increased binding to the switch-II pocket region. The *cis*-3-hydroxy-L-proline linker used in this study increased the potency 8-fold, demonstrating that high affinity linker modifications can enhance scaffold binding.

The performance of DOCKoValent is greatly dependent on the input structure. K-Ras is a highly flexible target, particularly in the switch-I and -II loops, which are integral to the ligand-binding site. This study was performed using ligand enrichment of fragment disulfides and vinylsulfonamides on 24 co-crystal structures of K-Ras inhibitors. However, the recent K-Ras^{G12C} inhibitor ARS-853 binds to an extended pocket, forming three hydrogen bonds⁷ and may not have ranked highly in the original docking screen against the smaller pockets found in earlier K-Ras co-crystal structures. In addition to ligand enrichment, ensemble docking with consensus ranking on distinct structural subsets may improve covalent ligand design against highly flexible targets. Or, perhaps, a flexible receptor procedure, which accounts for crystallographically observed alternative states of side chains and loops, could be incorporated into covalent docking to improve the results.¹²

This study further demonstrates that the switch-I and switch-II loops are tightly coordinated. The S-IIP binders can allosterically communicate across the loops to affect nucleotide recognition and Ras activity. Especially in flexible proteins, the empiric validation of ligand binding needs to consider thermodynamic stability of the ligand-protein interaction. The thermal stability assay demonstrated that 10 was thermodynamically destabilizing the protein. This destabilizing property

was consistent with increased H/D exchange and also with increased SOS-catalyzed nucleotide exchange of both GDP and GTP. Covalent binders may have destabilizing noncovalent interactions with the protein after covalent adduct formation.³⁴ Thus, the thermal stability assay may prove useful as a counter-screening method to measure the stabilizing noncovalent interactions during small molecule optimization. This assay may be particularly useful for classifying K-Ras switch-II compounds as allosteric inhibitors or potential nucleotide state destabilizers.

In this study, we describe a novel small molecule that destabilizes K-Ras and behaves like no other switch-II pocket binder in its unique ability to accelerate SOS-mediated nucleotide exchange. We believe this will help development of novel allosteric modulators of K-Ras that can be used to study aspects of nucleotide exchange.

METHODS

Covalent Docking. Covalent docking was performed using DOCKoValent as described and implemented in DOCK3.6.¹¹ The covalent bond parameters were set to length = 1.8 Å, bond angles = 109.5° \pm 10° (in 2.5° steps).

Protein Expression and Purification. K-Ras constructs were purified as previously specified.^{5,33}

X-ray Crystallization, Data Collection, and Refinement. For X-ray crystallography, 1 mM MgCl₂ and 40 μ M GDP (final concentration) was added to protein additionally purified through size exclusion chromatography. Hanging drop crystallization conditions were set up by mixing 1:1 protein and reservoir solutions. The reservoir contained 5% PEG400, 2 M (NH₄)₂SO₄, 0.1 M HEPES pH 7.5. After several days at 20 °C, crystals were observed. The crystals were cryoprotected in crystallization solution supplemented with 28% glycerol, flash frozen, and stored in liquid nitrogen prior to obtaining diffraction data at the 8.2.1 beamline at the Advanced Light Source of Lawrence Berkeley National Laboratories. Data was indexed with IMOSFLM and scaled and solved using Aimless and Phaser-MR (ccp4i) and then subsequently refined with Phenix to the indicated statistics in Table S4.³⁵

Synthesis. Few unsubstituted acrylamide fragments are available for purchase. Most acrylamide fragments were synthesized from commercially available 1° and 2° amines using 1.1-fold excess acryloyl chloride or acrylic acid as described in the Supporting Information. After purification, the compounds were made into 5 mM DMSO stocks.

Mass Spectrometry Screening. 50 μ L of 4 μ M K-Ras^{G12C} 1–169 or K-Ras^{WT} 1–189 was incubated with 200 or 25 μ M compound (4 or 2% v/v dimethyl sulfoxide respectively) for 24 h at room temperature. The reaction was quenched with 2 μ L 10% v/v formic acid to yield 0.4% v/v formic acid final. Mass spectrometry experiments were performed using the Waters Acquity UPLC/ESI-TQD with a 2.1 \times 50 mm Acquity UPLC BEH300 C4 column.

Nucleotide Exchange Assay. A 45 μ L portion of K-Ras(G12C)GDP (111 nM) was prepared in assay buffer (150 mM NaCl, 20 mM HEPES, pH 7.5, 104 μ M MgCl₂, 0.01% Tween) and was added to a 96 well Costar plate. Exchange was catalyzed by the addition of 5 μ L of a mixture of 2 μ M SOS and 2 μ M incoming nucleotide (200 nM final; ThermoFischer BODIPY-FL GDP or GTP) and fluorescence intensity was monitored over 1 h at E_x/E_m : 485/520 nm using a BioTek H4.

Thermal Stability Assays. The thermal denaturation of K-Ras was monitored using a fluorescence-based differential

scanning fluorimetry assay. K-Ras was purified with or without compound for the use of the experiment as previously described. A 8 μ M protein was prepared in assay buffer (150 mM NaCl, 20 mM Hepes, pH 7.5, 1 mM MgCl_2) with 1/1000 Sypro Orange. The plate was heated from 25 to 95 $^\circ\text{C}$ at a rate of 0.5 $^\circ\text{C}/\text{min}$. The fluorescence intensity was monitored at E_x/E_m : 492/610 nm.

Hydrogen–Deuterium Exchange Mass Spectrometry. HDX reactions were conducted with 40 pmol of protein and were initiated by the addition of 46 μL of D_2O buffer solution (10 mM HEPES pH 7.5, 50 mM NaCl, 97% D_2O), to give a final concentration of 87% D_2O . Exchange was carried out for 0.3, 3, 30, 300, and 3000 s, and exchange was terminated by the addition of a quench buffer (final concentration 0.6 M guanidine HCl, 0.8% formic acid). Samples were rapidly frozen in liquid nitrogen and stored at $-80\text{ }^\circ\text{C}$ until mass analysis.

Protein samples were rapidly thawed and injected onto a UPLC system at 2 $^\circ\text{C}$. The protein was run over two immobilized pepsin columns (Applied Biosystems; porosyme, 2-3131-00) at 10 and 2 $^\circ\text{C}$ at 200 $\mu\text{L}/\text{min}$ for 3 min, and peptides were collected onto a VanGuard precolumn trap (Waters). The trap was subsequently eluted in line with an Acquity 1.7 μm particle, $100 \times 1\text{ mm}^2$ C18 UPLC column (Waters), using a gradient of 5–36% B (buffer A 0.1% formic acid, buffer B 100% acetonitrile) over 16 min. Mass spectrometry experiments were performed on an Impact II TOF (Bruker) acquiring over a mass range from 150 to 2200 m/z using an electrospray ionization source operated at a temperature of 200 $^\circ\text{C}$ and a spray voltage of 4.5 kV. Peptides were identified using data-dependent acquisition methods following tandem MS/MS experiments (0.5 s precursor scan from 150 to 2200 m/z ; 12 0.25 s fragment scans from 150 to 2200 m/z). MS/MS data sets were analyzed using PEAKS7 (PEAKS), and a false discovery rate was set at 1% using a database of purified proteins and known contaminants.

Deuterium incorporation calculations were carried out as described previously.^{36–38} HD-Examiner Software (Sierra Analytics) was used to automatically calculate the level of deuterium incorporation into each peptide. All peptides were manually inspected for correct charge state and presence of overlapping peptides. Deuteration levels were calculated using the centroid of the experimental isotope clusters. Full set of all H/D exchange data are shown in Figure S5. Significant changes between conditions were set as changes greater than 6%, 0.5 Da, and a p -value < 0.05 (student t test).

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jcim.7b00399.

Structural alignment of 24 ligand-bound K-Ras structures; additional docking poses of ligands; relative % deuterium incorporation in all peptides in ligand bound K-Ras; deuterium incorporation over time in specific peptides; percent modification of K-Ras^{G12C} and K-Ras^{WT} for compounds screened in library via mass spectrometry; thermal stability data for optimized compound 12; data collection and refinement statistics for crystal structure of compound-10 bound K-Ras^{G12C}; synthetic methods and characterization for all compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: nir.london@weizmann.ac.il.

ORCID

Chimno I. Nnadi: 0000-0003-3003-7691

Daniel K. Nomura: 0000-0003-1614-8360

John E. Burke: 0000-0001-7904-9859

Kevan M. Shokat: 0000-0002-6900-8380

Nir London: 0000-0003-2687-0699

Author Contributions

C.I.N., N.L., and K.M.S. designed the study and wrote the manuscript with input from all authors. N.L. and D.Z. performed docking and computational analysis. C.I.N. and T.E.B. performed cheminformatics analysis. C.I.N., N.L., D.R.G., and L.A.B. synthesized small molecules for the initial screens. C.I.N. expressed and purified the protein and performed biochemical X-ray crystallography, and synthesized compounds for structure-activity relationships. M.L.J. and J.E.B. performed HDX-MS structural studies and analysis. D.Z. analyzed HRMS results. C.I.N., N.L., K.M.S. performed analysis of all biochemical results.

Funding

This work is supported by a National Institutes of Health Grant R01 (SR01CA190408) to K.M.S. and a F30 Kirschstein-NRSA (1F30CA214015) to C.I.N. This research was also supported by a Stand Up To Cancer–American Cancer Society Lung Cancer Dream Team Translational Research Grant to K.M.S. (SU2C-AACR-DT17-15). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. N.L. is the incumbent of the Alan and Laraine Fischer Career Development Chair. N.L. would like to acknowledge funding from the Israel Science Foundation (grant No. 1097/16), the Rising Tide Foundation, and a research career development award from the Israel Cancer Research Foundation. J.E.B. would like to acknowledge funding from the CIHR new investigator program as well as a discovery research grant from the Natural Sciences and Engineering Research Council of Canada (NSERC-2014-05218). D.K.N. would like to acknowledge funding from a National Institutes of Health Grant (SR01CA172667).

Notes

The authors declare the following competing financial interest(s): K.M.S. is an inventor on UCSF patents related to K-Ras (G12C) inhibitors licensed to Wellspring Biosciences. K.M.S. is a stockholder and consultant to Wellspring Biosciences.

■ ACKNOWLEDGMENTS

We thank Jonathan M. Ostrem for initial involvement in synthesis and characterization of small molecules; Ilana Rogachev and Asaph Aharoni for help with HRMS; Qi Hu and Lynn McGregor for discussion; and the staff at the Advanced Light Source, which is supported by the US Department of Energy under contract DE-AC02-05CH1123.

■ REFERENCES

(1) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The Resurgence of Covalent Drugs. *Nat. Rev. Drug Discovery* **2011**, 10 (4), 307–317.

- (2) De Cesco, S.; Kurian, J.; Dufresne, C.; Mittermaier, A. K.; Moitessier, N. Covalent Inhibitors Design and Discovery. *Eur. J. Med. Chem.* **2017**, *138*, 96–114.
- (3) Cohen, M. S.; Zhang, C.; Shokat, K. M.; Taunton, J. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. *Science* **2005**, *308* (5726), 1318–1321.
- (4) John, J.; Sohmen, R.; Feuerstein, J.; Linke, R.; Wittinghofer, A.; Goody, R. S. Kinetics of Interaction of Nucleotides with Nucleotide-Free H-Ras P21. *Biochemistry* **1990**, *29* (25), 6058–6065.
- (5) Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions. *Nature* **2013**, *503* (7477), 548–551.
- (6) Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: Fragment-Based Drug Discovery. *Annu. Rev. Biophys. Biomol. Struct.* **2004**, *33* (1), 199–223.
- (7) Patricelli, M. P.; Janes, M. R.; Li, L. S.; Hansen, R.; Peters, U.; Kessler, L. V.; Chen, Y.; Kucharski, J. M.; Feng, J.; Ely, T.; Chen, J. H.; Firdaus, S. J.; Babbar, A.; Ren, P.; Liu, Y. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. *Cancer Discovery* **2016**, *6*, 316.
- (8) Lito, P.; Solomon, M.; Li, L. S.; Hansen, R.; Rosen, N. Allele-Specific Inhibitors Inactivate Mutant KRAS G12C by a Trapping Mechanism. *Science* **2016**, *351*, 604.
- (9) Zeng, M.; Lu, J.; Li, L.; Feru, F.; Quan, C.; Gero, T. W.; Ficarro, S. B.; Xiong, Y.; Ambrogio, C.; Paranal, R. M.; Catalano, M.; Shao, J.; Wong, K.-K.; Marto, J. A.; Fischer, E. S.; Jänne, P. A.; Scott, D. A.; Westover, K. D.; Gray, N. S. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. *Cell Chem. Biol.* **2017**, *24* (8), 1005–1016.
- (10) Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases. *J. Med. Chem.* **2014**, *57* (11), 4969–4974.
- (11) London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermančič, P.; Bonnet, R.; Shoichet, B. K.; Taunton, J. Covalent Docking of Large Libraries for the Discovery of Chemical Probes. *Nat. Chem. Biol.* **2014**, *10* (12), 1066–1072.
- (12) Fischer, M.; Coleman, R. G.; Fraser, J. S.; Shoichet, B. K. Incorporation of Protein Flexibility and Conformational Energy Penalties in Docking Screens to Improve Ligand Discovery. *Nat. Chem.* **2014**, *6* (7), 575–583.
- (13) Teodoro, M. L.; Kavraki, L. E. Conformational Flexibility Models for the Receptor in Structure Based Drug Design. *Curr. Pharm. Des.* **2003**, *9* (20), 1635–1648.
- (14) Hritz, J.; de Ruiter, A.; Oostenbrink, C. Impact of Plasticity and Flexibility on Docking Results for Cytochrome P450 2D6: a Combined Approach of Molecular Dynamics and Ligand Docking. *J. Med. Chem.* **2008**, *51* (23), 7469–7477.
- (15) Rueda, M.; Totrov, M.; Abagyan, R. ALiBERO: Evolving a Team of Complementary Pocket Conformations Rather Than a Single Leader. *J. Chem. Inf. Model.* **2012**, *52* (10), 2705–2714.
- (16) Richter, L.; de Graaf, C.; Sieghart, W.; Varagic, Z.; Mörzinger, M.; de Esch, I. J. P.; Ecker, G. F.; Ernst, M. Diazepam-Bound GABAA Receptor Models Identify New Benzodiazepine Binding-Site Ligands. *Nat. Chem. Biol.* **2012**, *8* (5), 455–464.
- (17) Corbeil, C. R.; Moitessier, N. Docking Ligands Into Flexible and Solvated Macromolecules. 3. Impact of Input Ligand Conformation, Protein Flexibility, and Water Molecules on the Accuracy of Docking Programs. *J. Chem. Inf. Model.* **2009**, *49* (4), 997–1009.
- (18) Cosconati, S.; Marinelli, L.; Di Leva, F. S.; La Pietra, V.; De Simone, A.; Mancini, F.; Andrisano, V.; Novellino, E.; Goodsell, D. S.; Olson, A. J. Protein Flexibility in Virtual Screening: the BACE-1 Case Study. *J. Chem. Inf. Model.* **2012**, *52* (10), 2697–2704.
- (19) Li, N.; Sun, Z.; Jiang, F. SOFTDOCK Application to Protein-Protein Interaction Benchmark and CAPRI. *Proteins: Struct., Funct., Genet.* **2007**, *69* (4), 801–808.
- (20) Jiang, F.; Lin, W.; Rao, Z. SOFTDOCK: Understanding of Molecular Recognition Through a Systematic Docking Study. *Protein Eng., Des. Sel.* **2002**, *15* (4), 257–263.
- (21) Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-Dimensional Docking: a Fast and Accurate Account of Discrete Receptor Flexibility in Ligand Docking. *J. Med. Chem.* **2009**, *52* (2), 397–406.
- (22) Armen, R. S.; Chen, J.; Brooks, C. L. An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular Dynamics. *J. Chem. Theory Comput.* **2009**, *5* (10), 2909–2923.
- (23) Dietzen, M.; Zotenko, E.; Hildebrandt, A.; Lengauer, T. On the Applicability of Elastic Network Normal Modes in Small-Molecule Docking. *J. Chem. Inf. Model.* **2012**, *52* (3), 844–856.
- (24) Vinh, N. B.; Simpson, J. S.; Scammells, P. J.; Chalmers, D. K. Virtual Screening Using a Conformationally Flexible Target Protein: Models for Ligand Binding to P38 α MAPK. *J. Comput.-Aided Mol. Des.* **2012**, *26* (4), 409–423.
- (25) Barril, X.; Morley, S. D. Unveiling the Full Potential of Flexible Receptor Docking Using Multiple Crystallographic Structures. *J. Med. Chem.* **2005**, *48* (13), 4432–4443.
- (26) Nicholls, A. The Character of Molecular Modeling. *J. Comput.-Aided Mol. Des.* **2012**, *26* (1), 103–105.
- (27) Smith, J. M.; Rowley, C. N. Automated Computational Screening of the Thiol Reactivity of Substituted Alkenes. *J. Comput.-Aided Mol. Des.* **2015**, *29* (8), 725–735.
- (28) Flanagan, M. E.; Abramite, J. A.; Anderson, D. P.; Aulabaugh, A.; Dahal, U. P.; Gilbert, A. M.; Li, C.; Montgomery, J.; Oppenheimer, S. R.; Ryder, T.; Schuff, B. P.; Uccello, D. P.; Walker, G. S.; Wu, Y.; Brown, M. F.; Chen, J. M.; Hayward, M. M.; Noe, M. C.; Obach, R. S.; Philippe, L.; Shanmugasundaram, V.; Shapiro, M. J.; Starr, J.; Stroth, J.; Che, Y. Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors. *J. Med. Chem.* **2014**, *57* (23), 10072–10079.
- (29) Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-Based Lead Discovery: Leads by Design. *Drug Discovery Today* **2005**, *10* (14), 987–992.
- (30) Vadas, O.; Burke, J. E. Probing the Dynamic Regulation of Peripheral Membrane Proteins Using Hydrogen Deuterium Exchange-MS (HDX-MS). *Biochem. Soc. Trans.* **2015**, *43* (5), 773–786.
- (31) Harrison, R. A.; Engen, J. R. Conformational Insight Into Multi-Protein Signaling Assemblies by Hydrogen-Deuterium Exchange Mass Spectrometry. *Curr. Opin. Struct. Biol.* **2016**, *41*, 187–193.
- (32) Harrison, R. A.; Lu, J.; Carrasco, M.; Hunter, J.; Manandhar, A.; Gondi, S.; Westover, K. D.; Engen, J. R. Structural Dynamics in Ras and Related Proteins Upon Nucleotide Switching. *J. Mol. Biol.* **2016**, *428* (23), 4723–4735.
- (33) McGregor, L. M.; Jenkins, M. L.; Kerwin, C.; Burke, J. E.; Shokat, K. M. Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. *Biochemistry* **2017**, *56*, 3178.
- (34) Trehan, I.; Beadle, B. M.; Shoichet, B. K. Inhibition of AmpC Beta-Lactamase Through a Destabilizing Interaction in the Active Site. *Biochemistry* **2001**, *40* (27), 7992–7999.
- (35) Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a Comprehensive Python-Based System for Macromolecular Structure Solution. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66* (2), 213–221.
- (36) Siempelkamp, B. D.; Rathinaswamy, M. K.; Jenkins, M. L.; Burke, J. E. Molecular Mechanism of Activation of Class IA Phosphoinositide 3-Kinases (PI3Ks) by Membrane-Localized HRas. *J. Biol. Chem.* **2017**, *292*, 12256.
- (37) Dornan, G. L.; Siempelkamp, B. D.; Jenkins, M. L.; Vadas, O.; Lucas, C. L.; Burke, J. E. Conformational Disruption of PI3K δ Regulation by Immunodeficiency Mutations in PIK3CD and PIK3RI. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114* (8), 1982–1987.
- (38) Vadas, O.; Jenkins, M. L.; Dornan, G. L.; Burke, J. E. Using Hydrogen-Deuterium Exchange Mass Spectrometry to Examine Protein-Membrane Interactions. *Methods Enzymol.* **2017**, *583*, 143–172.